Health TrialsbyHealthPanel

Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy

ConditionMacular Dystrophy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNew Valley University

About this trial

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All patients diagnosed with macular dystrophy in Tiba Eye Centre, Egypt, Assiut, during the period of the study

Disqualifiers

The patients diagnosed with macular dystrophy refuse to contribute to the study.

Trial population

All patients diagnosed with macular dystrophy during the period of the study

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • OCT ,mFERG,VA test

    Diagnostic test

    retinal photography by OCT, VA measurement, and mfERG test

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

BCVA (best corrected visual acuity)

BCVA was recorded in 30 eyes of 30 patients with macular dystrophy.

Time frame
Day 1/month 3
2

CMT (central macular thickness) μm Central macular thickness measurement using optical coherence tomography

CMT (central macular thickness) in μm in 30 eyes of 30 patients with macular dystrophy Central macular thickness measurement using optical coherence tomography.

Time frame
Day1/month 3
3

mf-ERG amplituide nV/deg2

mf-ERG amplitude nV/deg² in 30 eyes of 30 patients with macular dystrophy multifocal electroretinogram amplitude measurement using the mf-ERG machine

Time frame
Day 1/month 6

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

New Valley University

Lead sponsor

Assiut University

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: